BTCRC-LYM17-145
Phase Ib dose de-escalation study of the PI3K alpha/delta inhibitor, Copanlisib given in combination with the immunotherapeutic agents, Nivolumab and Rituximab in patients with relapsed/refractory indolent lymphoma. Big Ten Cancer Research Consortium BTCRC-LYM17-145
Status: Open to Accrual
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter